Emcitate (Tiratricol): A New Treatment for MCT8 Deficiency and Allan-Herndon-Dudley Syndrome
Emcitate, whose active ingredient is tiratricol, is a specialized thyroid hormone therapy developed for people with a rare genetic disorder known as monocarboxylate transporter 8 (MCT8) deficiency, also called Allan-Herndon-Dudley syndrome (AHDS). The medication has received increasing attention because it addresses an unusual problem in thyroid hormone biology: patients can have excessive thyroid hormone activity in some tissues while simultaneously experiencing inadequate thyroid hormone action in the brain. In September 2026, the U.S. Food and Drug Administration (FDA) approved Emcitate as the first FDA-approved treatment for peripheral thyrotoxicosis associated with MCT8 deficiency in adults and children (U.S. Food and Drug Administration [FDA], 2026). Emcitate had previously received marketing authorization in the European Union in 2025 (European Medicines Agency [EMA], 2025).
MCT8 deficiency is an extremely rare X-linked disorder caused by pathogenic variants in the SLC16A2 gene. The MCT8 protein normally helps thyroid hormones, particularly triiodothyronine (T3), enter and leave cells. When MCT8 is deficient, thyroid hormone transport into the brain is severely disrupted. At the same time, thyroid hormone levels in other tissues can become excessively high, producing a condition known as peripheral thyrotoxicosis. This unusual combination contributes to severe neurological impairment as well as metabolic and cardiovascular complications (Groeneweg et al., 2019; EMA, 2025).
What Is Tiratricol?
Tiratricol, also known as triiodothyroacetic acid or Triac, is a thyroid hormone analogue that is structurally related to T3. Unlike T3, however, tiratricol can enter cells without relying on the defective MCT8 transporter. This property is central to its therapeutic effect in MCT8 deficiency (EMA, 2025).
The basic therapeutic concept is relatively straightforward. In MCT8 deficiency, thyroid hormone cannot be transported normally into the brain. Tiratricol can bypass this defective transport mechanism and enter cells through other pathways, allowing it to activate thyroid hormone receptors. At the same time, its actions help reduce excessive circulating T3 concentrations and lessen the consequences of peripheral thyrotoxicosis (FDA, 2026; EMA, 2025).
This makes Emcitate different from conventional thyroid replacement therapy. It is not simply intended to replace a missing thyroid hormone in a patient with ordinary hypothyroidism. Instead, it is designed to correct a very specific disorder of thyroid hormone transport and action.
What Is MCT8 Deficiency?
MCT8 deficiency is a rare genetic condition that primarily affects males because the SLC16A2 gene is located on the X chromosome. The disorder interferes with the transport of thyroid hormones into cells, particularly neurons in the developing brain. As a result, affected children can develop profound intellectual and motor disability, including severe impairment of head control, sitting, walking, speech, and other developmental milestones (EMA, 2025).
The disease also produces a distinctive pattern of abnormal thyroid hormone levels. Circulating T3 can become very high, while tissues that depend heavily on MCT8 for thyroid hormone transport experience inadequate thyroid hormone activity. This creates a form of peripheral thyrotoxicosis alongside what has been described as cerebral hypothyroidism (Groeneweg et al., 2019).
Peripheral thyrotoxicosis can contribute to symptoms such as rapid heart rate, elevated blood pressure, low body weight, muscle wasting, excessive sweating, and other metabolic abnormalities. Over time, these effects can contribute to serious cardiovascular and nutritional complications. The neurological effects are even more profound because thyroid hormone signaling is essential for normal brain development.
How Does Emcitate Work?
Tiratricol works primarily by acting as a thyroid hormone receptor agonist. Because it does not require MCT8 for cellular entry, it can reach tissues that cannot adequately receive T3 through the normal transport pathway. According to the EMA, this allows tiratricol to enter cells in individuals with MCT8 deficiency and help restore thyroid hormone activity (EMA, 2025).
An additional benefit is that tiratricol suppresses thyroid-stimulating hormone (TSH) secretion through feedback mechanisms. This can reduce endogenous production of thyroid hormones and contribute to the reduction of excessive circulating T3. The result is a more favorable thyroid hormone profile and a reduction in some manifestations of peripheral thyrotoxicosis (Groeneweg et al., 2019).
The medication therefore addresses two related problems: insufficient thyroid hormone action in MCT8-dependent tissues and excessive thyroid hormone activity in peripheral tissues. This dual effect is one of the most important scientific features of tiratricol.
The Evidence Behind Emcitate
The development of Emcitate was supported by clinical research involving children and adults with MCT8 deficiency. One important phase 2 international study enrolled 46 participants and evaluated tiratricol treatment over 12 months. The study was open-label and single-arm, meaning that participants received the treatment without a concurrent placebo control group (Groeneweg et al., 2019).
Among participants with available follow-up data, mean serum T3 concentrations decreased substantially, from approximately 4.97 nmol/L at baseline to 1.82 nmol/L after 12 months. Researchers also observed improvements in several manifestations of peripheral thyrotoxicosis, including resting heart rate, systolic blood pressure, and weight relative to age (Groeneweg et al., 2019). The EMA similarly reported substantial reductions in mean T3 levels and supportive improvements in cardiovascular measures (EMA, 2025).
These findings provided important evidence that tiratricol can correct the biochemical abnormality associated with MCT8 deficiency and reduce several peripheral manifestations of the disease. However, interpreting the evidence requires attention to the design of the original study. Because it was open-label and did not include a parallel placebo group, the results do not provide the same level of evidence as a large randomized, placebo-controlled clinical trial.
New Evidence Supporting U.S. Approval
The 2026 FDA approval was based on evidence from two clinical studies, including an international multicenter randomized placebo-controlled withdrawal study and a longer-term open-label study (FDA, 2026). The FDA reported that patients treated with Emcitate experienced reductions in excessive circulating thyroid hormone levels as well as improvements in cardiovascular and metabolic measures affected by thyrotoxicosis.
One of the trials, identified as NCT05579327, evaluated what happens when tiratricol is withdrawn from patients who had achieved stable treatment. The study was designed to assess whether discontinuing tiratricol would lead to a rebound in serum T3 levels compared with continued treatment. The study's design provides additional evidence concerning the medication's role in maintaining control of abnormal thyroid hormone levels.
The FDA's September 2026 approval represents an important development for patients with MCT8 deficiency because it provides the first FDA-approved therapy specifically intended to address the peripheral thyrotoxicosis associated with the disorder (FDA, 2026).
What Are the Symptoms of MCT8 Deficiency?
The clinical presentation of MCT8 deficiency can vary, but severe neurological disability is a defining feature. Many affected children experience delayed motor development, abnormal muscle tone, impaired coordination, and profound intellectual disability. Some individuals develop movement abnormalities and difficulty with voluntary motor control.
The peripheral consequences of the disease may include low body weight, muscle wasting, rapid heart rate, elevated blood pressure, excessive sweating, and other symptoms caused by excessive thyroid hormone activity outside the brain. These manifestations can become clinically significant and contribute to long-term cardiovascular and metabolic complications (Groeneweg et al., 2019).
Recognizing MCT8 deficiency can be challenging because the laboratory pattern differs from conventional thyroid disorders. Genetic testing and specialized thyroid hormone evaluation are often necessary to establish the diagnosis.
How Is Emcitate Administered?
Emcitate is an oral medication supplied as tablets intended to be dispersed in water before administration. According to the current U.S. prescribing information, the prepared suspension can be given orally or through an enteral feeding tube, which is particularly relevant for individuals with severe swallowing difficulties (FDA, 2026).
The dose is individualized according to factors such as body weight, serum total T3 concentrations, and clinical signs and symptoms of thyrotoxicosis. Treatment requires careful titration because excessive thyroid hormone activity can occur if the dose is too high (FDA, 2026).
The FDA labeling specifies that the tablets should not be swallowed whole, chewed, or crushed. They are intended to be dispersed in room-temperature drinking water according to the prescribed preparation instructions.
Side Effects and Safety Considerations
As with any thyroid-active medication, Emcitate must be carefully monitored. The most commonly reported adverse reactions in the FDA-approved labeling include diarrhea, vomiting, rash, and excessive sweating or hyperhidrosis (FDA, 2026).
Signs of excessive thyroid hormone activity can also develop, particularly during initiation or dose increases. These may include increased heart rate, elevated blood pressure, diarrhea, sweating, irritability, insomnia, and nightmares. Clinicians therefore adjust the dose according to laboratory results and clinical symptoms.
Another important issue is laboratory monitoring. Tiratricol can interfere with some immunoassays used to measure T3, potentially producing unreliable results or an overestimation of circulating T3. The FDA recommends measuring total T3 using liquid chromatography-tandem mass spectrometry when monitoring patients receiving Emcitate (FDA, 2026).
Who Should Not Take Emcitate?
Emcitate is a highly specialized therapy and is not intended for ordinary thyroid conditions. The current FDA labeling contraindicates its use in primary hyperthyroidism and states that it is not recommended for primary hypothyroidism (FDA, 2026).
Importantly, Emcitate is also not a weight-loss medication. The FDA-approved labeling contains a boxed warning stating that thyroid hormones, including Emcitate, should not be used to treat obesity or for weight loss. Excessive thyroid hormone activity can produce serious or life-threatening complications (FDA, 2026).
The EMA likewise states that Emcitate should not be used for other causes of hyperthyroidism and should not be used during pregnancy under its European product information (EMA, 2025).
Emcitate Is Not the Same as Conventional Thyroid Replacement
It is important not to confuse Emcitate with medications routinely prescribed for hypothyroidism, such as levothyroxine. Levothyroxine is synthetic T4 and is generally used to replace insufficient thyroid hormone production. Emcitate, by contrast, is a T3 analogue designed specifically to bypass a defective thyroid hormone transport mechanism.
The goal is also different. A person with ordinary hypothyroidism typically needs replacement of deficient thyroid hormone. A person with MCT8 deficiency has a transport problem in which hormone levels may be abnormal in opposite directions across different tissues. Treating the two conditions therefore requires very different strategies.
The FDA specifically advises that Emcitate should not be used together with other thyroid medications unless directed by an appropriate specialist, because combined therapy can alter thyroid hormone effects and increase the complexity of treatment (FDA, 2026).
Potential Impact on Cardiovascular and Metabolic Health
One of the important benefits of tiratricol therapy is its effect on peripheral thyrotoxicosis. Excessive thyroid hormone signaling can increase heart rate and cardiovascular workload and contribute to abnormal metabolism and muscle breakdown.
In the phase 2 trial, tiratricol treatment was associated with a reduction in resting heart rate and systolic blood pressure as serum T3 levels improved (Groeneweg et al., 2019). The FDA also reported improvements in cardiovascular and metabolic symptoms in patients receiving Emcitate in clinical studies (FDA, 2026).
These improvements are clinically meaningful because MCT8 deficiency is not solely a neurological disorder. The abnormal thyroid hormone environment can affect multiple organ systems, making metabolic and cardiovascular management an important part of comprehensive care.
The Importance of Early Treatment
MCT8 deficiency is particularly serious because thyroid hormone is essential for early brain development. Researchers have therefore been interested in whether beginning tiratricol treatment early in life could influence developmental outcomes.
Preclinical research has suggested that restoring thyroid hormone action during critical periods of brain development may have potential benefits. However, determining the extent to which treatment can alter established neurological disability in humans remains a difficult scientific question. The clinical trials have demonstrated clear biochemical and peripheral benefits, but evidence concerning long-term neurodevelopmental outcomes continues to evolve (Groeneweg et al., 2019; EMA, 2025).
This is one reason ongoing pediatric research remains important. The treatment may be most effective when integrated into a broader care plan involving neurology, endocrinology, rehabilitation, nutrition, physical therapy, and developmental services.
Emcitate and Rare-Disease Medicine
The approval of Emcitate illustrates the importance of developing treatments for rare diseases. Individuals with ultra-rare genetic disorders may have limited treatment options because relatively small patient populations make conventional drug-development programs difficult.
In the European Union, Emcitate received orphan designation, reflecting the rarity and serious nature of MCT8 deficiency. The EMA concluded that the available evidence supported authorization because the medication reduced peripheral thyrotoxicosis and improved relevant clinical measures in affected patients (EMA, 2025).
The FDA subsequently granted Emcitate several development-related designations, including Orphan Drug, Rare Pediatric Disease, Fast Track, and Breakthrough Therapy designations before approving it in September 2026 (FDA, 2026). These programs are designed to facilitate development and review of therapies for serious conditions with substantial unmet medical needs.
Future Research
Although Emcitate is now an approved treatment, research into tiratricol and MCT8 deficiency is continuing. Important questions remain concerning long-term safety, optimal treatment initiation during infancy, developmental outcomes, cardiac effects, skeletal muscle health, and the extent to which correcting the peripheral hormone imbalance can influence long-term disease outcomes.
Long-term follow-up is particularly important because MCT8 deficiency is a lifelong genetic disease. The EMA has identified continued monitoring of long-term safety and clinical outcomes as an important part of the medicine's ongoing evaluation (EMA, 2025).
Future studies may also provide a clearer understanding of whether early treatment can improve specific aspects of neurological development. This question is especially significant for infants and very young children, when thyroid hormones play a critical role in brain maturation.
Conclusion
Emcitate (tiratricol) represents an important advance in the treatment of MCT8 deficiency, a rare and severe genetic disorder that disrupts thyroid hormone transport. By acting as a thyroid hormone analogue that does not depend on the MCT8 transporter, tiratricol can bypass the defective pathway, reduce excessive circulating T3 levels, and improve several manifestations of peripheral thyrotoxicosis (EMA, 2025).
Clinical studies have demonstrated substantial reductions in T3 concentrations along with improvements in measures such as heart rate, blood pressure, and weight-related metabolic abnormalities. The FDA's September 2026 approval of Emcitate provides the first U.S.-approved therapy specifically for peripheral thyrotoxicosis associated with MCT8 deficiency (FDA, 2026).
At the same time, Emcitate is not a general thyroid medication, a treatment for ordinary hypothyroidism, or a weight-loss drug. It is a specialized therapy for a specific rare genetic condition and requires careful dosing and monitoring by clinicians experienced in managing thyroid disorders and rare diseases. As long-term studies continue, Emcitate may provide additional insight into how targeted thyroid hormone therapy can address both the metabolic and systemic consequences of MCT8 deficiency.
References
European Medicines Agency. (2025). Emcitate (tiratricol): EPAR—Medicine overview. https://www.ema.europa.eu/en/medicines/human/EPAR/emcitate
Groeneweg, S., Peeters, R. P., Moran, C., Stoupa, A., Auriol, F., Tonduti, D., Dica, A., Paone, L., Rozenkova, K., Malikova, J., van der Walt, A., de Coo, I. F. M., McGowan, A., Lyons, G., Aarsen, F. K. A., Barca, D., van Beynum, I. M., van der Knoop, M. M., Jansen, J., ... Visser, W. E. (2019). Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: An international, single-arm, open-label, phase 2 trial. The Lancet Diabetes & Endocrinology, 7(9), 695–706. https://doi.org/10.1016/S2213-8587(19)30155-X
U.S. Food and Drug Administration. (2026, September 28). FDA approves first treatment for MCT8 deficiency. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-mct8-deficiency
U.S. Food and Drug Administration. (2026). Emcitate (tiratricol) tablets for oral suspension: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220963s000lbl.pdf
Comments